Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 6Phase NA 4Phase 3 3Phase 1 3Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Myelodysplastic Syndromes 9Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Neuroblastoma 5Lymphoma, Non-Hodgkin 5Leukemia 5Rhabdoid Tumor 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Wilms Tumor 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Ganglioneuroblastoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × Stem Cell Transplantation × Clear all
NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT04483206 2025-05-31

Personalized Autologous Transplant for Multiple Myeloma

Emory University

Phase 1 Recruiting
90 enrolled
Plasma cell

Multiple Myeloma

NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡